Skip Navigation



Acta Biochimica et Biophysica Sinica Advance Access published online on April 8, 2009
Acta Biochimica et Biophysica Sinica, doi:10.1093/abbs/gmp027
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
41/5/429    most recent
gmp027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Feng, J.
Right arrow Articles by Zhou, Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Feng, J.
Right arrow Articles by Zhou, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer

Jifeng Feng1,2, Xinchen Sun3,*, Ning Sun3, Shukui Qin4, Fan Li3, Hongyan Cheng3, Baoan Chen3,*, YuanDong Cao3, Jun Ma3, Lu Cheng5, Zuhong Lu5, Jiazhong Ji6 and Yingfeng Zhou6

1 Medical School, Southeast University, Nanjing 210009, China
2 Jiangsu Cancer Hospital, Nanjing 210009, China
3 Zhongda Hospital, Southeast University, Nanjing 210009, China
4 Department of Oncology, The 81th Hospital of PLA, Nanjing 210034, China
5 Laboratory of Molecular and Biomolecular Electronics, Southeast University, Nanjing 210096, China
6 Department of Oncology, Jiangbei People Hospital, Nanjing 210048, China

* Correspondence address. Tel: +86-25-83275408 (X.S.)/+86-25-83272006 (B.C.); Fax: +86-25-83272011 (X.S.)/+86-25-83272011 (B.C); E-mail: sunxch505{at}yahoo.com.cn (X.S.), cba8888{at}hotmail.com (B.C.)


  Abstract

DNA repair capacity (DRC) is correlated with sensitivity of cancer cells toward platinum-based chemotherapy. We hypothesize that genetic polymorphisms in DNA repair gene XPA (xeroderma pigmentosum group A) and XPG (xeroderma pigmentosum group G) (ERCC5, excision repair cross-complementation group 5), which result in inter-individual differences in DNA repair efficiency, may predict clinical response to platinum agents in advanced non-small cell lung cancer (NSCLC) patients. In this study, we find that the A -> G change of XPA A23G polymorphism significantly increased response to platinum-based chemotherapy. Polymorphism in XPG His46His was associated with a decreased treatment response, but was not statistically significant.

Keywords    single nucleotide polymorphism; gene-chip; XPA; XPG; nucleotide excision repair; non-small cell lung cancer; chemotherapy

Received: December 3, 2008; Accepted: March 10, 2009
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.